05:41 PM EST, 03/06/2025 (MT Newswires) -- scPharmaceuticals (SCPH) said late Thursday the US Food and Drug Administration approved its supplemental new drug application to expand the use of Furoscix to treat edema in patients with chronic kidney disease.

The drug is expected to be available for chronic kidney disease patients in April, the company said.

Furoscix's use was previously limited as a treatment for edema in patients with chronic heart failure.

Shares of the company were up 5.2% in after-hours activity.

Price: 3.28, Change: +0.16, Percent Change: +5.21